A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

253 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-17

Study Completion Date

2018-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

NCT03487588

Seborrheic Keratosis

COMPLETED PHASE4

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920

Seborrheic Keratosis (SK)

COMPLETED PHASE1/PHASE2

Study of A-101 for the Treatment of Seborrheic Keratosis

NCT02260180

Seborrheic Keratosis

COMPLETED PHASE2

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

NCT02160626

Seborrheic Keratosis

COMPLETED PHASE2

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275

Seborrheic Keratosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.

The secondary objectives of this study include duration of response of A-101. During the study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face. For each subject, at least 1 SK Target Lesion must be on the face and at least 1 Target Lesion must be on the trunk or extremities. The Target Lesions will be treated at a maximum of two treatment visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seborrheic Keratosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vehicle

Vehicle Topical Solution

Group Type PLACEBO_COMPARATOR

A-101

Intervention Type DRUG

Topical Solution

A-101 Low Dose

A-101 Low Dose Topical Solution

Group Type ACTIVE_COMPARATOR

A-101

Intervention Type DRUG

Topical Solution

A-101 High Dose

A-101 High DoseTopical Solution

Group Type ACTIVE_COMPARATOR

A-101

Intervention Type DRUG

Topical Solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A-101

Topical Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is able to comprehend and is willing to sign an informed consent for participation in this study.
2. Male or female ≥ 18 years old.
3. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis.
4. Subject has 4 appropriate seborrheic keratosis Target Lesions on the trunk, extremities and face, with at least 1 Target Lesion on the face and at least 1 Target Lesion on the trunk or extremities. The 4 identified Target Lesions must meet the requirements as defined below:

1. Have a clinically typical appearance
2. Have a Physician's Lesion Assessment of ≥ 2
3. Length that is ≥ 5mm and ≤ 15mm
4. Width that is ≥ 5mm and ≤ 15 mm
5. Thickness that is ≤ 2mm
6. Be a discrete lesion
7. Be the only SK lesion present when centered in the area outlined by the provided circular template
8. Not be covered with hair which, the in the investigator's opinion, would interfere with the study medication treatment or the study evaluations
9. Not be in the intertriginous fold
10. Not be on the eyelids
11. Not be within 5mm of the orbital rim
12. Not be pedunculated
5. Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.
6. Woman of childbearing potential must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study.
7. Subject is non-pregnant and non-lactating.
8. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target Lesion or which exposes the subject to an unacceptable risk by study participation.
9. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria

1. Subject has clinically atypical and /or rapidly growing seborrheic keratosis lesions.
2. Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser - Trelat).
3. Subject has current systemic malignancy.
4. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

* Retinoids; 180 days
* Corticosteroids; 28 days
* Anti-metabolites (e.g., methotrexate); 28 days
5. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:

* LASER, light or other energy based therapy (e.g., intense pulsed light, photo-dynamic therapy; 180 days
* Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-Fluorouracil, or ingenol mebutate; 60 days
* Hydrogen peroxide: 90 days
* Retinoids; 28 days
* Microdermabrasion or superficial chemical peels; 14 days
* Corticosteroids or antibiotics; 14 days
6. Subject would require the use of any topical treatment (e.g. moisturizers, sunscreen) to any of the Target Lesions 12 hours prior to any study visit.
7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:

* Cutaneous malignancy; 180 days
* Sunburn; currently
* Pre-malignancy (e.g. actinic keratosis); currently
* Body art (e.g. tattoos, piercing, etc.); currently
* Excessive tan; currently. The use of self-tanning lotions/sprays are prohibited.
8. Subject has a history of sensitivity to any of the ingredients in the study medications.
9. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
10. Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No